Rezdiffra vs Ibsrela
A side-by-side look at two gastrointestinal medications advertised on TV. Informational only — not medical advice.
| US Rezdiffra | US Ibsrela | |
|---|---|---|
| Generic name | resmetirom | tenapanor |
| Drug class | Thyroid Hormone Receptor-Beta Agonist | Sodium/Hydrogen Exchanger 3 (NHE3) Inhibitor |
| Treats | Metabolic dysfunction-associated steatohepatitis (MASH) | Irritable bowel syndrome with constipation (IBS-C) |
| Category | Gastrointestinal | Gastrointestinal |
| Manufacturer | Madrigal Pharmaceuticals | Ardelyx |
| Year approved | 2024 | 2019 |
| FDA warning | Moderate warnings | Black box warning |
| Est. TV ad spend | — | — |
| Common side effects | Diarrhea, Nausea, Itching, Gallbladder problems | Diarrhea, Should not be used in young children (boxed warning), Gas, Abdominal pain |
Rezdiffra
Frequently asked questions
Is Rezdiffra or Ibsrela better?
Neither is universally "better." Rezdiffra (resmetirom) and Ibsrela (tenapanor) are both used for gastrointestinal, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Rezdiffra and Ibsrela?
Rezdiffra is a Thyroid Hormone Receptor-Beta Agonist made by Madrigal Pharmaceuticals, while Ibsrela is a Sodium/Hydrogen Exchanger 3 (NHE3) Inhibitor made by Ardelyx. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Rezdiffra has the larger estimated TV advertising budget of the two.